{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:39Z","timestamp":1789614159349,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004599","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104891","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:21:45Z","timestamp":1785770505000},"page":"104891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3966-1071","authenticated-orcid":false,"given":"Simon Peter","family":"Gampenrieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Castagnaviz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-6917","authenticated-orcid":false,"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3049-0261","authenticated-orcid":false,"given":"Thamer","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Dormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Suppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Heibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Scagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1893-7245","authenticated-orcid":false,"given":"Margit","family":"Sandholzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-2994","authenticated-orcid":false,"given":"Thomas","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August Felix","family":"Zabernigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-2226","authenticated-orcid":false,"given":"Clemens","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0283-8176","authenticated-orcid":false,"given":"Daniel","family":"Egle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Roitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Andel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3639-3232","authenticated-orcid":false,"given":"Kathrin","family":"Strasser-Weippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hubalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Knauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-0027","authenticated-orcid":false,"given":"Christian Fridolin","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7438-1465","authenticated-orcid":false,"given":"Gabriel","family":"Rinnerthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2026.104891_bib1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","article-title":"The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.breast.2026.104891_bib2","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104891_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2026.104891_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.phrs.2018.03.021","article-title":"Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases","volume":"132","author":"Shah","year":"2018","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104891_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","article-title":"Tissue concentration of systemically administered antineoplastic agents in human brain tumors","volume":"104","author":"Pitz","year":"2011","journal-title":"J Neuro Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104891_bib6","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B","article-title":"Central nervous system metastasis from breast carcinoma. Autopsy study","volume":"52","author":"Tsukada","year":"1983","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.breast.2026.104891_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.breast.2026.104891_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.breast.2020.02.007","article-title":"Clinical outcome of patients with brain metastases from breast cancer - a population based study over 21 years","volume":"50","author":"Thulin","year":"2020","journal-title":"Breast"},{"issue":"12","key":"10.1016\/j.breast.2026.104891_bib9","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1200\/JCO.2009.24.6314","article-title":"Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer","volume":"28","author":"Graesslin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104891_bib10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D","article-title":"The natural history of breast cancer patients with brain metastases","volume":"44","author":"DiStefano","year":"1979","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104891_bib11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/annonc\/mdp407","article-title":"Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)","volume":"21","author":"Niwi\u0144ska","year":"2010","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104891_bib12","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.asjsur.2021.12.037","article-title":"Brain metastasis in de novo breast cancer: an updated population-level study from SEER database","volume":"45","author":"Sun","year":"2022","journal-title":"Asian J Surg"},{"issue":"3","key":"10.1016\/j.breast.2026.104891_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104891_bib14","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/neuonc\/noae123","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch","year":"2024","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104891_bib15","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104891_bib16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104891_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-Positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2026.104891_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.breast.2026.104891_bib19","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2014.57.1794","article-title":"CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-Positive metastatic breast cancer","volume":"33","author":"Pivot","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104891_bib20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdu133","article-title":"Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA","volume":"25","author":"Swain","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104891_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104891_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104891_bib23","series-title":"Presented at ESMO Congress","author":"Geyer","year":"2025"},{"issue":"25","key":"10.1016\/j.breast.2026.104891_bib24","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-Mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.breast.2026.104891_bib25","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104891_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114175","article-title":"Impact of cyclin dependent kinase 4\/6 inhibitors on breast cancer brain metastasis outcomes","volume":"207","author":"Chew","year":"2024","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.breast.2026.104891_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103699","article-title":"Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial","volume":"9","author":"Vaz Batista","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.breast.2026.104891_bib28","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","article-title":"Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial","volume":"31","author":"Preusser","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.breast.2026.104891_bib29","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S1470-2045(25)00470-X","article-title":"Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Bartsch","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104891_bib30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/0284186X.2017.1418534","article-title":"Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014","volume":"57","author":"Jeene","year":"2018","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104891_bib31","first-page":"4859","article-title":"Discordance and conversion rates of Progesterone-, Estrogen-, and HER2\/neu-Receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy","volume":"37","author":"Timmer","year":"2017","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.breast.2026.104891_bib32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/neuonc\/noaa013","article-title":"Subtype switching in breast cancer brain metastases: a multicenter analysis","volume":"22","author":"Hulsbergen","year":"2020","journal-title":"Neuro Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:32:02Z","timestamp":1789612322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S0960977626002018"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104891","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104891"}}